Filing Flows › Senti Biosciences Holdings (SNTI) › Takeover & LBO
Is Senti Biosciences Holdings (SNTI) a takeover target?
A leveraged buyout does not work for Senti Biosciences Holdings on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. Latest signal (2026-09-24): Merger proxy (DEFM14A).
Why a leveraged buyout does not fit
The buyout model needs Senti Biosciences Holdings' revenue, EBITDA, share count and share price; not all of them are on file, so it gives no buyout price.
What a takeover could cost
Takeovers in its sector paid a median premium of 35% over the share price before the deal (the middle half 22% to 45%), according to the 15 merger proxies and tender-offer responses on EDGAR that state a premium.
Rumors and deal signals
- 2026-09-24 · DEFM14A · Merger proxy (DEFM14A)
Senti Biosciences Holdings' latest quarter
Senti Biosciences Holdings, Q2 2026: revenue $17K, net loss $12.8M, operating cash flow −$14.2M. The chart follows the revenue to costs, profit and cash.
Questions
Is Senti Biosciences Holdings being acquired?
The latest signal on file is from 2026-09-24: Merger proxy (DEFM14A). A headline is not a deal; Filing Flows lists the news, 8-K filings and 13D filings about a sale.
Could private equity buy Senti Biosciences Holdings?
A leveraged buyout does not work for Senti Biosciences Holdings on its latest figures: the figures a buyout model needs (revenue, EBITDA, the share count and the price) are not all on file. The model gives no buyout price until they are.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.